Value of Cancer Care—Which Model Is Best?
Originally presented at HOPA's 13th Annual Conference, March 2017.
This session will examine the dynamic landscape of value in cancer care and its impact on treatment decisions. The presenters will review cancer care costs and compare and contrast the available tools for assigning value to treatment options. Finally, we will debate the impact of these tools on patients, providers, organizations, payers, and the entire cancer care delivery system.
- Explore the strengths and weaknesses of readily available tools for assessing the value of cancer treatment options.
- Compare the clinical outcome and other impacts associated with the use of available value frameworks at the organizational and payer levels.
- Explore future directions in assessment of the value of cancer treatment options.
Jason Bergsbaken, PharmD BCOP
Jason Bergsbaken currently serves as pharmacy coordinator, Regional Oncology Services, for UW Health in Madison, WI. His responsibilities include the coordination and standardization of pharmaceutical care among UW Carbone Cancer Center partners. He received his PharmD degree from the University of Wisconsin–Madison. Following graduation, he completed a PGY-1 pharmacy practice residency and PGY-2 oncology pharmacy residency at UW Health. He also practices in the inpatient and ambulatory setting at UW Health and has been intimately involved with the implementation of multiple practice advancement initiatives, including pharmacist-led oral chemotherapy management.
Suwicha Limvorasak, PharmD BCOP
Suwicha Limvorasak, a pharmacy program coordinator at Cedars-Sinai Medical Center, has substantial experience in oncology research and in the clinical aspects of the practice of oncology pharmacy. She has been a board certified oncology pharmacist since 2008. She served as a voting member of the protocol scientific review and monitoring committee at Cedars-Sinai. She has served for several years on various HOPA committees. She received her PharmD degree from the University of Florida–Gainesville in 2005, followed by clinical training at the University of Chicago Medical Center, where she worked as a clinical pharmacist specialist until 2011.
Margaret Rausa, PharmD
Margaret Rausa has spent more than 11 years in managed care with a focus on specialty pharmacy and medical oncology. She currently serves as the vice president of clinical program development at eviCore healthcare and is an emerging leader in the field of clinical pathway development. Earlier she worked in the pharmacy benefit management industry, where she held roles in specialty pharmacy, including management of clinical programs and development of evidence-based utilization criteria. She earned her PharmD degree at the University of Illinois and completed a pharmacy residency specializing in analytics and outcomes.
Practice Administration & Development
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.
This activity has been approved for .125 CEUs
This course is also included as part of the Best of AC2017 Bundle product.
Release Date: August 31, 2017
Expiration Date: March 29, 2020